Investigation of IL-6 and IL-10 signalling via mathematical modelling

IET Systems Biology

Volumn 5, Issue 1, 2011, Pages 15-26

  Moya, C ^a   Huang, Z ^a   Cheng, P ^a   Jayaraman, A ^a   Hahn, J ^a  

^a Texas AandM University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVITY RATIOS; CYTOKINES; EXPERIMENTAL DATA; FAT CONTENTS; HEPATOCYTES; MATHEMATICAL MODELLING; NON-ALCOHOLIC FATTY LIVER DISEASE;

BACTERIOPHAGES; TRANSCRIPTION; TRANSCRIPTION FACTORS;

SIGNAL TRANSDUCTION;

CYTOKINE; DNA BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN; TRANSACTIVATOR PROTEIN;

HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

CYTOKINES; DNA-BINDING PROTEINS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS;

EID: 78751688567     PISSN: 17518849     EISSN: None     Source Type: Journal    
DOI: 10.1049/iet-syb.2009.0060     Document Type: Article

References (40)

1. McClain, C.J., Mokshagundam, S.P., and Barve, S.S.: et al. 'Mechanisms of non-alcoholic steatohepatitis', Alcohol, 2004, 34, p. 67-7910.1016/j.alcohol.2004.07.007
2. Sanyal, A.J.: 'Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease', Nat. Clin. Pract., 2005, 2, p. 46-5310.1038/ncpgasthep0084
3. Clark, J.M.: 'The epidemiology of nonalcoholic fatty liver disease in adults', J. Clin. Gastroenterol., 2006, 40, p. S5-S10
4. Méndez-Sánchez, N., Arrese, M., Zamora-Valdés, D., and Uribe, M.: 'Current concepts in the pathogenesis of nonalcoholic fatty liver disease', Liver Int., 2007, 27, p. 423-43310.1111/j.1478-3231.2007.01483.x
5. Lalor, P.F., Faint, J., Aarbodem, Y., Hubscher, S.G., and Adams, D.H.: 'The role of cytokines and chemokines in the development of steatohepatitis', Semin. Liver Dis., 2007, 27, p. 173-19310.1055/s-2007-979470
6. Diehl, A.M.: 'Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease', Clin. Liv. Dis., 2004, 8, p. 619-63810.1016/j.cld.2004.04.012
7. Rahman, S.M., Schroeder-Gloeckler, J.M., and Janssen, R.C.: et al. 'CCAAT/enhancing binding protein beta deletion in mice attenuates inflammation, endoplasmic reticulum stress, and lipid accumulation in diet-induced nonalcoholic steatohepatitis', Hepatoclogy, 2007, 45, p. 1108-111710.1002/hep.21614
8. Abiru, S., Migita, K., and Maeda, Y.: et al. 'Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis', Liver Int., 2006, 26, p. 39-4510.1111/j.1478-3231.2005.01191.x
9. Willner, I.R., Waters, B., Patil, S.R., Reuben, A., Morelli, J., and Riely, C.A.: 'Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease', Am. J. Gastroenterol., 2001, 96, p. 2957-296110.1111/j.1572-0241.2001.04667.x
10. Videla, L.A., Rodrigo, R., Araya, J., and Poniachik, J.: 'Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease', Trends Mol. Med., 2006, 12, p. 555-55810.1016/j.molmed.2006.10.001
11. Heinrich, P.C., Behrmann, I., Muller-Newen, G., Schaper, F., and Graeve, L.: 'Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway', Biochem. J., 1998, 334, (Pt 2), p. 297-314
12. Sengupta, T.K., Talbot, E.S., Scherle, P.A., and Ivashkiv, L.B.: 'Rapid inhibition of interleukin-6 signalling and Stat3 activation mediated by mitogen-activated protein kinases', Proc. Natl. Acad. Sci., 1998, 95, p. 11107-1111210.1073/pnas.95.19.11107
13. Hong, F., Radaeva, S., Pan, H.N., Tian, Z., Veech, R., and Gao, B.: 'Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease', Hepatology, 2004, 40, p. 933-94110.1002/hep.20400
14. Inoue, H., Ogawa, W., and Ozaki, M.: et al. 'Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo', Nat. Med., 2004, 10, p. 168-17410.1038/nm980
15. Ueki, K., Kondo, T., Tseng, Y.H., and Kahn, C.R.: 'Central role of suppressors of cytokine signalling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse', Proc. Natl. Acad. Sci. USA, 2004, 101, p. 10422-1042710.1073/pnas.0402511101 0027-8424
16. Murray, P.J.: 'The JAK-STAT signalling pathway: input and output integration', J. Immunol., 2007, 178, p. 2623-2629
17. Murray, P.J.: 'Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response', Curr. Opin. Pharmacol., 2006, 6, p. 379-38610.1016/j.coph.2006.01.010
18. Schoeberl, B., Eichler-Jonsson, C., Gilles, E.D., and Muller, G.: 'Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors', Nat. Biotechnol., 2002, 20, p. 370-37510.1038/nbt0402-370
19. Yamada, S., Shionoa, S., Joob, A., and Yoshimura, A.: 'Control mechanism of JAK/STAT signal transduction pathway', FEBS Lett., 2003, 534, p. 190-19610.1016/S0014-5793(02)03842-5
20. Singh, A., Jayaraman, A., and Hahn, J.: 'Modeling regulatory mechanisms in IL-6 signal transduction in hepatocytes', Biotechnol. Bioeng., 2006, 95, (5), p. 850-86210.1002/bit.21026
21. Huang, Z., Chu, Y., Senocak, F., Jayaraman, A., and Hahn, J.: 'Model update of signal transduction pathways in hepatocytes based upon sensitivity analysis', Proc. Foundations of Systems Biology 2007, Stuttgart, Germany 2007, p. 45-50
22. Corvinus, F.M., Orth, C., and Morigg, R.: et al. 'Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth', Neoplasia, 2005, 7, (6), p. 545-55510.1593/neo.04571
23. Judd, L.M., Alderman, B.M., and Howlett, M.: et al. 'Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130', Gastroenterology, 2004, 126, (1), p. 196-20710.1053/j.gastro.2003.10.066
24. Heinrich, P.C., Behrmann, I., Haan, S., Hermanns, H.M., Muller-Newen, G., and Schaper, F.: 'Principles of interleukin (IL)-6-type cytokine signalling and its regulation', Biochem. J., 2003, 374, p. 1-2010.1042/BJ20030407
25. Huang, Z., Senocak, F., Jayaraman, A., and Hahn, J.: 'Integrated modeling and experimental approach for determining transcription factor profiles from fluorescent reporter data', BMC Syst. Biol., 2008, 2, p. 6410.1186/1752-0509-2-64
26. Chu, Y., Jayaraman, A., and Hahn, J.: 'Parameter sensitivity analysis of IL-6 signaling pathways', IET Syst. Biol., 2007, 1, (6), p. 342-35210.1049/iet-syb:20060053
27. Frank, P.M.: 'Introduction to system sensitivity theory', (Academic Press, New York 1978)
28. Tomovic, R., and Vukobratovic, M.: 'General sensitivity theory', (Elsevier, New York 1972)
29. Cukier, R.I., Fortuin, C.M., Shuler, K.E., Petschek, A.G., and Schaibly, J.H.: 'Study of the sensitivity of coupled reaction systems to uncertainties in rate coefficients-I theory', J. Chem. Phys., 1973, 59, (8), p. 3873-387810.1063/1.1680571 0021-9606
30. McRae, G.J., Tilden, J.W., and Seinfeld, J.H.: 'Global sensitivity analysis-a computational implementation of the Fourier amplitude sensitivity test (FAST)', Comput. Chem. Eng., 1982, 6, (1), p. 15-2510.1016/0098-1354(82)80003-3 0098-1354
31. Rearden, B.T.: 'Perturbation theory eigenvalue sensitivity analysis with Monte Carlo techniques', Nucl. Sci. Eng., 2004, 146, p. 367-3820029-5639
32. Helton, J.C., Davis, F.J., and Johnson, J.D.: 'A comparison of uncertainty and sensitivity analysis results obtained with random and Latin hypercube sampling', Reliab. Eng. Syst. Saf., 2005, 89, p. 305-33010.1016/j.ress.2004.09.006 0951-8320
33. McKay, M.D., Beckman, R.J., and Conover, W.J.: 'A comparison of three methods for selecting values of input variables in the analysis of output from a computer code', Technometrics, 2000, 42, (1), p. 55-6110.2307/1271432 0040-1706
34. Zi, Z.K., Cho, K.H., Sung, M.H., Xia, X.F., Zheng, J.S., and Sun, Z.R.: 'In silico identification of the key components and steps in INF-γ induced JAK-STAT signalling pathway', FEBS Lett., 2005, 579, p. 1101-110810.1016/j.febslet.2005.01.009
35. Fischer, P., and Hilfiker-Kleiner, D.: 'Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects', Br. J. Pharmacol., 2008, 153, p. S414-S42710.1038/bjp.2008.1
36. Fischer, P., Lehmann, U., and Sobota, R.M.: et al. 'The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling', Biochem. J., 2004, 378, p. 449-46010.1042/BJ20030893
37. Lang, R., Pauleau, A.L., and Parganas, E.: et al. 'SOCS3 regulates the plasticity of gp130 signalling', Nat. Immunol., 2003, 4, p. 546-55010.1038/ni932
38. Fasshauer, M., Kralisch, S., and Klier, M.: et al. 'Insulin resistance-inducing cytokines differentially regulate SOCS mRNA expression via growth factor- and Jak/Stat-signalling pathways in 3T3-L1 adipocytes', J. Endocrinol., 2004, 181, p. 129-13810.1677/joe.0.1810129
39. King, K.R., Wang, S., Irimia, D., Jayaraman, A., Toner, M., and Yarmush, M.L.: 'A high-throughput microfluidic real-time gene Expression living cell array', Lab Chip, 2007, 7, p. 7710.1039/b612516f 1473-0197
40. Roth, C.M., Kohen, R.L., Walton, S.P., and Yarmush, M.L.: 'Coupling of inflammatory cytokine signalling pathways probed by measurements of extracellular acidification rate', Biophys. Chem., 2001, 89, p. 1-1210.1016/S0301-4622(00)00212-X